As an upstream factor of the MAPK or PI3K pathway, the high expression and carcinogenesis of TMEFF1 in endometrial carcinoma may have potential for the diagnosis of diseases, monitoring of cancer progression, and immunotargeted therapy, and become a new target for the treatment of endometrial carcinoma. This evidence concerns the gene TMEFF1 and cancer.